Published in Antimicrob Agents Chemother on February 01, 2005
Age-related effects on nelfinavir and M8 pharmacokinetics: a population study with 182 children. Antimicrob Agents Chemother (2006) 1.01
Nelfinavir and Lamivudine pharmacokinetics during the first two weeks of life. Pediatr Infect Dis J (2011) 0.92
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med (1997) 17.51
Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med (1997) 10.62
Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm (1981) 6.53
Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. N Engl J Med (1997) 3.71
Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. N Engl J Med (1999) 2.67
Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data. J Pharmacokinet Biopharm (1981) 1.88
Guidelines for the use of antiretroviral agents in pediatric HIV infection. Center for Disease Control and Prevention. MMWR Recomm Rep (1998) 1.60
Nelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric AIDS Clinical Trials Group Protocol 377. Pediatrics (2003) 1.57
Predictors of optimal virological response to potent antiretroviral therapy. AIDS (1999) 1.40
Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities. Antimicrob Agents Chemother (2001) 1.37
Nelfinavir: an update on its use in HIV infection. Drugs (2000) 1.35
Drug interactions of HIV protease inhibitors. Drug Saf (1999) 1.24
Design, synthesis, and evaluation of nonpeptidic inhibitors of human rhinovirus 3C protease. J Med Chem (1996) 1.19
Pharmacokinetics of nelfinavir in human immunodeficiency virus-infected infants. Pediatr Infect Dis J (2001) 1.18
Pharmacokinetics of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1. Pediatr Infect Dis J (2003) 1.13
Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate. Clin Infect Dis (1999) 1.10
Preliminary experiences with triple therapy including nelfinavir and two reverse transcriptase inhibitors in previously untreated HIV-infected children. AIDS (1999) 1.06
Nelfinavir mesylate: a protease inhibitor. Ann Pharmacother (1999) 0.96
Pk-fit: a pharmacokinetic/pharmacodynamic and statistical data analysis software. Comput Biomed Res (2000) 0.93
Pharmacokinetics and pharmacodynamics of nelfinavir administered twice or thrice daily to human immunodeficiency virus type 1-infected children. Clin Infect Dis (2003) 0.93
Dose-escalating study of the safety and pharmacokinetics of nelfinavir in HIV-exposed neonates. J Acquir Immune Defic Syndr (2002) 0.88
Pharmacokinetics of nelfinavir in children: influencing factors and dose implications. Antivir Ther (2003) 0.88
The pharmacokinetics of nelfinavir in HIV-1-infected children. Ther Drug Monit (2002) 0.82
Nelfinavir. Drugs (1997) 0.78
Nelfinavir pharmacokinetics in HIV-infected children: a comparison of twice daily and three times daily dosing. AIDS (2000) 0.78
First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. Lancet Infect Dis (2011) 3.04
Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol Drug Saf (2010) 2.57
Drug administration errors and their determinants in pediatric in-patients. Int J Qual Health Care (2005) 2.31
Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring. Arch Dis Child (2012) 2.28
Virologic, immunologic, and clinical benefits from early combined antiretroviral therapy in infants with perinatal HIV-1 infection. AIDS (2006) 2.26
Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS (2008) 2.19
Recruitment in pediatric clinical research was influenced by study characteristics and pediatricians' perceptions: a multicenter survey. J Clin Epidemiol (2013) 2.19
PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. HIV Med (2009) 2.16
Age and CD4 count at initiation of antiretroviral therapy in HIV-infected children: effects on long-term T-cell reconstitution. J Infect Dis (2011) 2.13
Multicenter prospective study of the burden of rotavirus acute gastroenteritis in Europe, 2004-2005: the REVEAL study. J Infect Dis (2007) 1.99
Drug use in children: cohort study in three European countries. BMJ (2008) 1.91
Modulation of erythroid adhesion receptor expression by hydroxyurea in children with sickle cell disease. Haematologica (2008) 1.87
Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost? Clin Infect Dis (2012) 1.80
Incidence of mucocutaneous reactions in children treated with niflumic acid, other nonsteroidal antiinflammatory drugs, or nonopioid analgesics. Pediatrics (2005) 1.55
Nosocomial rotavirus infection in European countries: a review of the epidemiology, severity and economic burden of hospital-acquired rotavirus disease. Pediatr Infect Dis J (2006) 1.54
Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants. AIDS (2009) 1.49
Effects of nutritional rehabilitation on intestinal function and on CD4 cell number in children with HIV. J Pediatr Gastroenterol Nutr (2002) 1.43
Effects of recombinant human growth hormone for 1 year on body composition and muscle strength in children on long-term steroid therapy: randomized controlled, delayed-start study. J Clin Endocrinol Metab (2013) 1.43
Intussusception among young children in Europe. Pediatr Infect Dis J (2006) 1.42
Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected children. J Acquir Immune Defic Syndr (2005) 1.41
Clinical manifestations and socio-economic impact of influenza among healthy children in the community. J Infect (2011) 1.40
Factors associated with mother-to-child transmission of HIV-1 despite a maternal viral load <500 copies/ml at delivery: a case-control study nested in the French perinatal cohort (EPF-ANRS CO1). Clin Infect Dis (2010) 1.36
Feasibility of early infant diagnosis of HIV in resource-limited settings: the ANRS 12140-PEDIACAM study in Cameroon. PLoS One (2011) 1.30
Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy. Br J Clin Pharmacol (2011) 1.29
Changing patterns of clinical events in perinatally HIV-1-infected children during the era of HAART. AIDS (2007) 1.28
Persistence of multidrug-resistant HIV-1 without antiretroviral treatment 2 years after sexual transmission. Antivir Ther (2004) 1.26
No relation between in-utero exposure to HAART and intrauterine growth retardation. AIDS (2009) 1.24
Impact of community-acquired paediatric rotavirus gastroenteritis on family life: data from the REVEAL study. BMC Fam Pract (2010) 1.24
Assessment of pediatric asthma drug use in three European countries; a TEDDY study. Eur J Pediatr (2010) 1.19
Burden of community-acquired and nosocomial rotavirus gastroenteritis in the pediatric population of Western Europe: a scoping review. BMC Infect Dis (2012) 1.16
Five-year follow-up of children with perinatal HIV-1 infection receiving early highly active antiretroviral therapy. BMC Infect Dis (2009) 1.14
Immune reconstitution in HIV-1-infected children on antiretroviral therapy: role of thymic output and viral fitness. AIDS (2002) 1.14
Distribution of rotavirus genotypes in Europe, 2004-2005: the REVEAL Study. J Infect Dis (2007) 1.13
Pharmacokinetics of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1. Pediatr Infect Dis J (2003) 1.13
Early therapy in HIV-1-infected children: effect on HIV-1 dynamics and HIV-1-specific immune response. Antivir Ther (2008) 1.13
Economics of rotavirus gastroenteritis and vaccination in Europe: what makes sense? Pediatr Infect Dis J (2006) 1.10
Diclofenac and metabolite pharmacokinetics in children. Paediatr Anaesth (2004) 1.09
Harmonization process for the identification of medical events in eight European healthcare databases: the experience from the EU-ADR project. J Am Med Inform Assoc (2012) 1.09
Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics. Pharmacogenomics (2011) 1.09
Defining off-label and unlicensed use of medicines for children: results of a Delphi survey. Pharmacol Res (2008) 1.08
Ciprofloxacin safety in paediatrics: a systematic review. Arch Dis Child (2011) 1.07
Older children and adolescents surviving with vertically acquired HIV infection. J Acquir Immune Defic Syndr (2002) 1.07
Databases for pediatric medicine research in Europe--assessment and critical appraisal. Pharmacoepidemiol Drug Saf (2008) 1.07
External Evaluation of Population Pharmacokinetic Models of Vancomycin in Neonates: The transferability of published models to different clinical settings. Br J Clin Pharmacol (2013) 1.07
EU-ADR healthcare database network vs. spontaneous reporting system database: preliminary comparison of signal detection. Stud Health Technol Inform (2011) 1.06
Population analysis of the pregnancy-related modifications in lopinavir pharmacokinetics and their possible consequences for dose adjustment. J Antimicrob Chemother (2009) 1.05
Long-term decay of the HIV-1 reservoir in HIV-1-infected children treated with highly active antiretroviral therapy. J Infect Dis (2006) 1.05
Pregnancy and HIV infection: A european consensus on management. AIDS (2002) 1.04
Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia. Eur J Clin Pharmacol (2012) 1.03
Paediatric drug development: are population models predictive of pharmacokinetics across paediatric populations? Br J Clin Pharmacol (2011) 1.03
Rotavirus types in Europe and their significance for vaccination. Pediatr Infect Dis J (2006) 1.01
Maternal immune response and neonatal seroprotection from a single dose of a monovalent nonadjuvanted 2009 influenza A(H1N1) vaccine: a single-group trial. Ann Intern Med (2011) 1.00
Real-time PCR measurement of persistence of Bordetella pertussis DNA in nasopharyngeal secretions during antibiotic treatment of young children with pertussis. J Clin Microbiol (2008) 0.99
Clinical and socioeconomic impact of different types and subtypes of seasonal influenza viruses in children during influenza seasons 2007/2008 and 2008/2009. BMC Infect Dis (2011) 0.99
Prevalence of herpesviruses at onset of idiopathic nephrotic syndrome. Pediatr Nephrol (2014) 0.99
Ciprofloxacin use in neonates: a systematic review of the literature. Pediatr Infect Dis J (2011) 0.98
Clinical trials of rotavirus vaccines in Europe. Pediatr Infect Dis J (2006) 0.98
Toll-like receptor 9 polymorphisms influence mother-to-child transmission of human immunodeficiency virus type 1. J Transl Med (2010) 0.98
The prescribing of analgesics and non-steroidal anti-inflammatory drugs in paediatric primary care in the UK, Italy and the Netherlands. Pharmacol Res (2010) 0.98
Comparison of antiepileptic drug prescribing in children in three European countries. Epilepsia (2009) 0.97
Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents. AIDS (2008) 0.96
Localization and mRNA expression of CYP3A and P-glycoprotein in human duodenum as a function of age. Drug Metab Dispos (2005) 0.96
Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients. Ther Drug Monit (2005) 0.96
European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in Europe: executive summary. J Pediatr Gastroenterol Nutr (2008) 0.96
Early detection of colonization by VIM-1-producing Klebsiella pneumoniae and NDM-1-producing Escherichia coli in two children returning to France. J Clin Microbiol (2011) 0.95
Multinomial logistic estimation of Markov-chain models for modeling sleep architecture in primary insomnia patients. J Pharmacokinet Pharmacodyn (2010) 0.95
Early highly active antiretroviral therapy enhances B-cell longevity: a 5 year follow up. Pediatr Infect Dis J (2014) 0.95
Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist. J Psychopharmacol (2011) 0.95
Prevention of mother-to-child HIV transmission: similar access for sub-Sahara African immigrants and for French women? AIDS (2008) 0.95
Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model. BMC Public Health (2011) 0.95
Safety of fluconazole in paediatrics: a systematic review. Eur J Clin Pharmacol (2013) 0.94
Mycophenolate mofetil for steroid-dependent nephrotic syndrome: a phase II Bayesian trial. Pediatr Nephrol (2011) 0.94
The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women. AIDS (2013) 0.93
Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen. Cancer Chemother Pharmacol (2003) 0.93
Idiopathic acute liver injury in paediatric outpatients: incidence and signal detection in two European countries. Drug Saf (2013) 0.93
Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children. Clin Infect Dis (2008) 0.93
Intraperitoneal administration of novel doxorubicin loaded polymeric delivery systems against peritoneal carcinomatosis: experimental study in a murine model of ovarian cancer. Gynecol Oncol (2011) 0.92
Phenotype and genotype for thiopurine methyltransferase activity in the French Caucasian population: impact of age. Eur J Clin Pharmacol (2004) 0.92
The immunological and virological consequences of planned treatment interruptions in children with HIV infection. PLoS One (2013) 0.92
Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder. Neuropsychopharmacology (2006) 0.92
Polymorphisms of innate immunity genes influence disease progression in HIV-1-infected children. AIDS (2012) 0.92
A European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA). Arch Dis Child (2011) 0.91
Physiopathology of idiopathic nephrotic syndrome: lessons from glucocorticoids and epigenetic perspectives. Pediatr Nephrol (2011) 0.91
Antifungal prophylaxis in neonates. Early Hum Dev (2011) 0.90
Pregnancy outcomes in women with HIV type-1 receiving a lopinavir/ritonavir-containing regimen. Antivir Ther (2009) 0.90
Innovative study design for paediatric clinical trials. Eur J Clin Pharmacol (2011) 0.90
Population pharmacokinetics and pharmacogenetics of once daily prolonged-release formulation of tacrolimus in pediatric and adolescent kidney transplant recipients. Eur J Clin Pharmacol (2012) 0.90
Liquid chromatography-electrospray mass spectrometry determination of carbamazepine, oxcarbazepine and eight of their metabolites in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 0.90
Use of combination neonatal prophylaxis for the prevention of mother-to-child transmission of HIV infection in European high-risk infants. AIDS (2013) 0.90
Malaria prevention reduces in-hospital mortality among severely ill tuberculosis patients: a three-step intervention in Bissau, Guinea-Bissau. BMC Infect Dis (2011) 0.89
Immune reconstitution and vaccination outcome in HIV-1 infected children: present knowledge and future directions. Hum Vaccin Immunother (2012) 0.89
European survey on the use of prophylactic fluconazole in neonatal intensive care units. Eur J Pediatr (2011) 0.89